Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00003107
What this trial is testing

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+8 more
Indiana University
Early research (Phase 1)Ended earlyNCT02254239
What this trial is testing

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Mayo Clinic 10
Early research (Phase 1)Ended earlyNCT00005787
What this trial is testing

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNeutropenia
Northwestern University 3
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more
Miltenyi Biomedicine GmbH 315
Testing effectiveness (Phase 2)Active Not RecruitingNCT03179917
What this trial is testing

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Looking for participantsNCT03418038
What this trial is testing

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Who this might be right for
Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic 80
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Early research (Phase 1)Study completedNCT01535989
What this trial is testing

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Who this might be right for
B-cell Lymphoma Refractory
Cristiana Sessa 25
Testing effectiveness (Phase 2)Study completedNCT00575068
What this trial is testing

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Biogen 42
Testing effectiveness (Phase 2)Ended earlyNCT02811679
What this trial is testing

Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Massachusetts General Hospital 13
Early research (Phase 1)Ended earlyNCT02706405
What this trial is testing

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma+3 more
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT06486051
What this trial is testing

Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+1 more
Malaghan Institute of Medical Research 60
Early research (Phase 1)WithdrawnNCT05037669
What this trial is testing

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
University of Pennsylvania
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Study completedNCT01217229
What this trial is testing

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Daiichi Sankyo 20
Testing effectiveness (Phase 2)Ended earlyNCT03401853
What this trial is testing

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more
University of Washington 18
Testing effectiveness (Phase 2)Study completedNCT00005080
What this trial is testing

506U78 in Treating Patients With Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaRecurrent Adult T-cell Leukemia/Lymphoma+11 more
National Cancer Institute (NCI) 74
Testing effectiveness (Phase 2)UnknownNCT04239170
What this trial is testing

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Peking University 84
Early research (Phase 1)Not Yet RecruitingNCT06385522
What this trial is testing

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Who this might be right for
NHLCutaneous T Cell LymphomaPeripheral T-cell Lymphoma
Boston Immune Technologies and Therapeutics 37
Next Page